Tirzepatide maintenance: the SURMOUNT-4 evidence The SURMOUNT-4 trial used a randomized-withdrawal design: all participants took open-label tirzepatide for 36 weeks (reaching a mean weight reduction of about 20.9%), then were randomized either to continue the drug or switch to placebo for another 52 weeks
The time the test mouse spent interacting with each was recorded for ten minutes, and a sociability index was calculated to quantify its preference for social interaction
In a diabetes MRI substudy, liver fat fell up to 47% at 15 mg versus about 11% on insulin. In biopsy-confirmed fatty-liver disease with fibrosis, a large share of participants on 15 mg had disease resolution versus a small share on placebo. These are not microdose data
In Mod GRF 1-29, four of the original amino acids have been modified, to enhance its stability
Retatrutide leads on early efficacy signal and liver-fat effect
Now that GLP-1 receptor agonists have entered the market as injectable treatments, patients naturally assume all injectable diabetes medications work the same way